Press release
Follicular Lymphoma Pipeline 2024: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights by DelveInsights | AstraZeneca, InnoCare Pharma, Allogene Therapeutics, HUTCHMED, Sound Biologics, Xynomic Pharma
"Follicular Lymphoma Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Follicular Lymphoma Market.
The Follicular Lymphoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Follicular Lymphoma Pipeline Report: https://www.delveinsight.com/sample-request/follicular-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Follicular Lymphoma treatment therapies with a considerable amount of success over the years.
• Follicular Lymphoma companies working in the treatment market are InnoCare Pharma, Allogene Therapeutics, HUTCHMED, Sound Biologics, Xynomic Pharmaceuticals, ADC Therapeutics, AstraZeneca, Dr Reddy's Laboratories, MAB WORKS, and others, are developing therapies for the Follicular Lymphoma treatment
• Emerging Follicular Lymphoma therapies in the different phases of clinical trials are- ICP 248, ALLO-501, HMPL-689, PSB 202, Abexinostat, Loncastuximab tesirine, Acalabrutinib, DRL_RI, MIL62, and others are expected to have a significant impact on the Follicular Lymphoma market in the coming years.
• In August 2024, The company plans to submit a supplemental Biologics License Application for tafasitamab as a treatment for FL patients who have not responded to at least one prior systemic anti-CD20 immunotherapy or chemo-immunotherapy by the end of 2024, following the positive results from the Phase III trial.
• In June 2024, A consortium comprising Eugene Private Equity and Korea Development Bank Private Equity announced its plans to acquire 80% of the South Korean vaccine manufacturer Boryung Biopharma Co. for 320 billion won (approximately USD 231 million).
• In February 2024, Incyte announced the completion of an asset purchase agreement with MorphoSys AG, granting Incyte exclusive global rights to tafasitamab. As a result, Incyte will assume responsibility for all US commercialization and clinical development costs and revenues, while MorphoSys will no longer receive future milestone payments, profit splits, or royalties.
Follicular Lymphoma Overview
Follicular lymphoma is a type of non-Hodgkin lymphoma (NHL), which is a cancer that originates in the lymphatic system, a part of the body's immune system. Follicular lymphoma specifically arises from abnormal growth of B-lymphocytes, a type of white blood cell, within the lymph nodes.
Get a Free Sample PDF Report to know more about Follicular Lymphoma Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/follicular-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging Follicular Lymphoma Drugs Under Different Phases of Clinical Development Include:
• ICP 248: InnoCare Pharma
• ALLO-501: Allogene Therapeutics
• HMPL-689: HUTCHMED
• PSB 202: Sound Biologics
• Abexinostat: Xynomic Pharmaceuticals
• Loncastuximab tesirine: ADC Therapeutics
• Acalabrutinib: AstraZeneca
• DRL_RI: Dr Reddy's Laboratories
• MIL62: MAB WORKS
Follicular Lymphoma Route of Administration
Follicular Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
Follicular Lymphoma Molecule Type
Follicular Lymphoma Products have been categorized under various Molecule types, such as
• Oligonucleotide
• Peptide
• Small molecule
Follicular Lymphoma Pipeline Therapeutics Assessment
• Follicular Lymphoma Assessment by Product Type
• Follicular Lymphoma By Stage and Product Type
• Follicular Lymphoma Assessment by Route of Administration
• Follicular Lymphoma By Stage and Route of Administration
• Follicular Lymphoma Assessment by Molecule Type
• Follicular Lymphoma by Stage and Molecule Type
DelveInsight's Follicular Lymphoma Report covers around 50+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Follicular Lymphoma product details are provided in the report. Download the Follicular Lymphoma pipeline report to learn more about the emerging Follicular Lymphoma therapies
https://www.delveinsight.com/sample-request/follicular-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key companies in the Follicular Lymphoma Therapeutics Market include:
Key companies developing therapies for Follicular Lymphoma are - Epizyme, Eisai, Bayer Healthcare Pharmaceuticals, Verastem Oncology, Gilead Sciences, TG Therapeutics, ADC Therapeutics, Incyte Corporation, MorphoSys, AbbVie, Janssen Research & Development, Regeneron Pharmaceuticals, Novartis, MEI Pharma, BeiGene, Xynomic Pharmaceuticals, Bristol Myers Squibb, and others.
Follicular Lymphoma Pipeline Analysis:
The Follicular Lymphoma pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Follicular Lymphoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Follicular Lymphoma Treatment.
• Follicular Lymphoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Follicular Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Follicular Lymphoma market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Follicular Lymphoma drugs and therapies
https://www.delveinsight.com/sample-request/follicular-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Follicular Lymphoma Pipeline Market Drivers
• Increase in prevalence of Follicular Lymphoma, emergence of effective novel therapies, increased Research and Developmental Activities are some of the important factors that are fueling the Follicular Lymphoma Market.
Follicular Lymphoma Pipeline Market Barriers
• However, lack Of Cost-Effective Treatment, progression of disease within 2 years (POD24) in the Disease and other factors are creating obstacles in the Follicular Lymphoma Market growth.
Scope of Follicular Lymphoma Pipeline Drug Insight
• Coverage: Global
• Key Follicular Lymphoma Companies: InnoCare Pharma, Allogene Therapeutics, HUTCHMED, Sound Biologics, Xynomic Pharmaceuticals, ADC Therapeutics, AstraZeneca, Dr Reddy's Laboratories, MAB WORKS, and others
• Key Follicular Lymphoma Therapies: ICP 248, ALLO-501, HMPL-689, PSB 202, Abexinostat, Loncastuximab tesirine, Acalabrutinib, DRL_RI, MIL62, and others
• Follicular Lymphoma Therapeutic Assessment: Follicular Lymphoma current marketed and Follicular Lymphoma emerging therapies
• Follicular Lymphoma Market Dynamics: Follicular Lymphoma market drivers and Follicular Lymphoma market barriers
Request for Sample PDF Report for Follicular Lymphoma Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/follicular-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Follicular Lymphoma Report Introduction
2. Follicular Lymphoma Executive Summary
3. Follicular Lymphoma Overview
4. Follicular Lymphoma- Analytical Perspective In-depth Commercial Assessment
5. Follicular Lymphoma Pipeline Therapeutics
6. Follicular Lymphoma Late Stage Products (Phase II/III)
7. Follicular Lymphoma Mid Stage Products (Phase II)
8. Follicular Lymphoma Early Stage Products (Phase I)
9. Follicular Lymphoma Preclinical Stage Products
10. Follicular Lymphoma Therapeutics Assessment
11. Follicular Lymphoma Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Follicular Lymphoma Key Companies
14. Follicular Lymphoma Key Products
15. Follicular Lymphoma Unmet Needs
16 . Follicular Lymphoma Market Drivers and Barriers
17. Follicular Lymphoma Future Perspectives and Conclusion
18. Follicular Lymphoma Analyst Views
19. Appendix
20. About DelveInsight
Related Reports:
Follicular Lymphoma Market https://www.delveinsight.com/report-store/follicular-lymphoma-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Follicular Lymphoma Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
Follicular Lymphoma Epidemiology https://www.delveinsight.com/report-store/follicular-lymphoma-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Follicular Lymphoma Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports:
• Percutaneous Arterial Closure Device Market: https://www.delveinsight.com/report-store/vascular-closure-devices-market
• Transdermal Drug Delivery Devices: https://www.delveinsight.com/report-store/transdermal-drug-delivery-devices-market
• Infusion Pumps Market: https://www.delveinsight.com/report-store/infusion-pumps-market
• Acute Radiation Syndrome Market: https://www.delveinsight.com/report-store/acute-radiation-syndrome-pipeline-insight
• Human Papillomavirus Hpv Market: https://www.delveinsight.com/report-store/human-papillomavirus-hpv-market
• Blood Gas And Electrolyte Analyzers Market: https://www.delveinsight.com/report-store/blood-gas-and-electrolyte-analyzers-market
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Follicular Lymphoma Pipeline 2024: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights by DelveInsights | AstraZeneca, InnoCare Pharma, Allogene Therapeutics, HUTCHMED, Sound Biologics, Xynomic Pharma here
News-ID: 3852245 • Views: …
More Releases from DelveInsight Business Research
Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals.
Objective of the Case Study
The…
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics.
According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than…
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies.
Biopsy devices play a crucial role in disease diagnosis by…
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide.
DelveInsight's General Surgery Devices Market Report 2032 provides…
More Releases for Follicular
Key Trends Reshaping the Follicular Lymphoma Treatment Market: Technological Adv …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Follicular Lymphoma Treatment Market Size Growth Forecast: What to Expect by 2025?
In recent years, there has been robust growth in the size of the follicular lymphoma treatment market. The market is projected to expand from $3.05 billion in 2024 to $3.28 billion in 2025, with a compound annual…
Follicular Lymphoma Market to Reach USD 6.74 Billion by 2034
Follicular lymphoma (FL) is the second most common type of non-Hodgkin lymphoma (NHL), accounting for roughly 20-30% of NHL cases worldwide. It is generally an indolent (slow-growing) B-cell malignancy, but it can transform into aggressive lymphoma in some patients. With advancements in immunotherapy, monoclonal antibodies, and targeted therapies, treatment outcomes have improved, offering patients longer remission periods and better quality of life.
Download Full PDF Sample Copy of Market Report @…
Follicular Lymphoma Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Follicular Lymphoma Pipeline Insight 2024" report provides comprehensive insights about 50+ Follicular Lymphoma companies and 50+ pipeline drugs in the Follicular Lymphoma pipeline landscape. It covers the Follicular Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Follicular Lymphoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways…
Follicular Lymphoma Pipeline Insights Report 2024
DelveInsight's, "Follicular Lymphoma Pipeline Insight 2024" report provides comprehensive insights about 50+ Follicular Lymphoma companies and 50+ pipeline drugs in the Follicular Lymphoma pipeline landscape. It covers the Follicular Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Follicular Lymphoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways…
Global Follicular Lymphoma Treatment Industry Opportunities, Analysis & Forecast …
Dhirtek Business Research and Consulting most recent study on the follicular lymphoma treatment market provides a comprehensive view of the entire market. The research report delves deeply into the global follicular lymphoma treatment market's drivers and restraints. Analysts have extensively researched the global follicular lymphoma treatment market's milestones and the current trends that are expected to determine its future. Primary and secondary research methods were used to create an in-depth…
Follicular Unit Extraction (FUE) Systems Market 2021 | Detailed Report
ReportsnReports publishes the report titled Follicular Unit Extraction (FUE) Systems that presents a 360-degree overview of the market under one roof. The report is developed with the meticulous efforts of an enthusiastic and experienced team of experts, analyts, and researchers that makes the report a valuable asset for stakeholders to make robust decisions. This report also provides an in-depth overview of product type, specification, technology, and production analysis considering vital…
